Work

FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication

Year: 2017
Type: article
Author: U.S. Food & Drug Administration
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: closed
OpenAlex ID: W4243752273
FWCI: 7.329
Cites:
Cited by: 158
Related to: 10